TG Therapeutics Stock News

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2021 Results - Earnings Call Transcript

TG Therapeutics press release (TGTX): Q4 GAAP EPS of -$0.70 misses by $0.08.Revenue of $2.32M (+5700.0% Y/Y) beats by $0.08M.

Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET

Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (NASDAQ:TGTX) is scheduled to announce Q4 esults on Tuesday, Mar. 1, before market open.Consensus EPS estimate is -$0.68 and consensus revenue estimate is $2.4M

NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACT

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials eva

TGTX is trading like a junk stock after the FDA announced that it is investigating umbralisib in CLL over safety concerns. However, people tend to forget, ublituximab for MS is the heart of TGTX.

TG Therapeutics <> is trading lower after the FDA announced an ongoing investigation over the increased risk of death related to the companys cancer medicine